COYA THERAPEUTICS INC宣布了一项由研究者发起的研究成果。该研究聚焦于低剂量IL-2(Ld Il-2)与CTLA4-Ig联合疗法在额颞叶痴呆患者中的应用。
研究数据表明,该疗法能够有效增强调节性T细胞的功能。同时,在治疗过程中,患者的认知能力表现出稳定性。这一结果为相关疾病的治疗提供了新的潜在方向。
COYA THERAPEUTICS INC宣布了一项由研究者发起的研究成果。该研究聚焦于低剂量IL-2(Ld Il-2)与CTLA4-Ig联合疗法在额颞叶痴呆患者中的应用。
研究数据表明,该疗法能够有效增强调节性T细胞的功能。同时,在治疗过程中,患者的认知能力表现出稳定性。这一结果为相关疾病的治疗提供了新的潜在方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.